Cargando…
Risk factors associated with treated acute-onset hypersensitivity reactions after COVID-19 mRNA vaccinations
Autores principales: | Pandya, Shalin, Macy, Eric, Crawford, William, Burnette, Amber, Sheikh, Javed, Shi, Jiaxiao, Chung, Joanie, Gin, Nancy, Zhang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Mosby, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804441/ http://dx.doi.org/10.1016/j.jaci.2021.12.215 |
Ejemplares similares
-
Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination–Associated Hypersensitivity Reactions
por: Macy, Eric, et al.
Publicado: (2022) -
Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022) -
Delayed Hypersensitivity Reactions Following First Dose of the SARS-CoV2 mRNA Vaccines
por: Xu, Jennifer, et al.
Publicado: (2021) -
Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination
por: Frustaci, Andrea, et al.
Publicado: (2022) -
Incidence and Risk Factors of Immediate Hypersensitivity Reactions and Immunization Stress-Related Responses With COVID-19 mRNA Vaccine
por: Imai, Kazuo, et al.
Publicado: (2022)